3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Endocrine
2
CNS
2
Genitourinary
1
Conditions
von Hippel-Lindau Disease
2
Pheochromocytoma
2
Paraganglioma
2
Neuroectodermal Tumors, Primitive
1
Hemangioblastoma
1
Carcinoma, Renal Cell
1
Adenoma, Islet Cell
1
Interventions
3-Iodobenzylguanidine
14
Temozolomide
6
lutetium Lu 177 dotatate
5
gallium Ga 68 dotatate
4
anlotinib
4
Specimen Handling
4
Everolimus
4
Radiotherapy
3
Phenoxybenzamine
3
Magnetic Resonance Spectroscopy
3
Doxorubicin
3
6-fluorodopamine
3
3-fluorobenzylguanidine
3
pegfilgrastim
2
olaparib
2
fluorodopa F 18
2
cabozantinib
2
belzutifan
2
Nivolumab
2
Ifosfamide
2
Granulocyte Colony-Stimulating Factor
2
Fluorodeoxyglucose F18
2
Filgrastim
2
Doxazosin
2
Dexmedetomidine
2
Capecitabine
2
Biopsy
2
Axitinib
2
Adrenalectomy
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Pheochromocytoma
×
belzutifan
×
Endocrine
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA
NCT07167329
2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2
Recruiting
100 enrolled